Insmed Incorporated (INSM) Acquires Transave, Inc.
12/2/2010 7:44:02 AM
More...
|
Transave, Inc.: ARIKACE(TM) Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients
10/21/2010 11:58:55 AM
More...
|
Transave, Inc. ARIKACE(TM) Demonstrates Sustained Benefit in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
6/17/2010 12:00:12 PM
More...
|
Transave, Inc. Issued Key Composition of Matter Patent for ARIKACE(TM)
5/24/2010 8:31:12 AM
More...
|
Transave, Inc. Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections
10/19/2009 10:42:56 AM
More...
|
Transave, Inc. Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections
9/14/2009 9:08:55 AM
More...
|
Transave, Inc. Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
6/25/2009 10:39:42 AM
More...
|
Transave, Inc. Completes Enrollment in Arikace(TM) Phase II Bronchiectasis Study
4/21/2009 8:54:16 AM
More...
|
Transave, Inc. Secures $12.5 Million in New Financing
10/2/2008 9:52:29 AM
More...
|
Transave, Inc. Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis
6/13/2008 9:51:14 AM
More...
|
|